Treatment of Francisella infections via PLGA- and lipid-based nanoparticle delivery of antibiotics in a zebrafish model.
We tested the efficiency of 2 different antibiotics, rifampicin and oxolinic acid, against an established infection caused by fish pathogen Francisella noatunensis ssp. orientalis (F.n.o.) in zebrafish. The drugs were tested in the free form as well as encapsulated into biodegradable nanoparticles, either polylactic-co-glycolic acid (PLGA) nanoparticles or nanostructured lipid carriers. The most promising therapies were PLGA-rifampicin nanoparticles and free oxolinic acid; the PLGA nanoparticles significantly delayed embryo mortality while free oxolinic acid prevented it. Encapsulation of rifampicin in both PLGA and nanostructured lipid carriers enhanced its efficiency against F.n.o. infection relative to the free drug. We propose that the zebrafish model is a robust, rapid system for initial testing of different treatments of bacterial diseases important for aquaculture.
['Ulanova|Lilia S|LS|', 'Pinheiro|Marina|M|', 'Vibe|Carina|C|', 'Nunes|Claudia|C|', 'Misaghian|Dorna|D|', 'Wilson|Steven|S|', 'Zhu|Kaizheng|K|', 'Fenaroli|Federico|F|', 'Winther-Larsen|Hanne C|HC|', 'Reis|Salette|S|', 'Griffiths|Gareth|G|']
D000818:Animals D000900:Anti-Bacterial Agents D005393:Fish Diseases D005603:Francisella D016905:Gram-Negative Bacterial Infections D019344:Lactic Acid D008055:Lipids D053758:Nanoparticles D010093:Oxolinic Acid D011100:Polyglycolic Acid D000077182:Polylactic Acid-Polyglycolic Acid Copolymer D012293:Rifampin D015027:Zebrafish
Infection Nanoparticles Antibiotics Danio rerio Francisella orientalis Zebrafish embryo